{"protocolSection":{"identificationModule":{"nctId":"NCT05072080","orgStudyIdInfo":{"id":"EBSI-CV-317-004"},"organization":{"fullName":"Bavarian Nordic","class":"INDUSTRY"},"briefTitle":"A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 (CHIKV VLP Vaccine)","officialTitle":"A Phase 3 Safety, Immunogenicity, and Lot-Consistency Trial of the VLP-Based Chikungunya Vaccine PXVX0317 in Healthy Adults and Adolescents"},"statusModule":{"statusVerifiedDate":"2024-08","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2021-09-29","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2023-04-03","type":"ACTUAL"},"completionDateStruct":{"date":"2023-04-03","type":"ACTUAL"},"studyFirstSubmitDate":"2021-09-28","studyFirstSubmitQcDate":"2021-09-28","studyFirstPostDateStruct":{"date":"2021-10-08","type":"ACTUAL"},"resultsFirstSubmitDate":"2024-04-02","resultsFirstSubmitQcDate":"2024-08-06","resultsFirstPostDateStruct":{"date":"2024-08-30","type":"ACTUAL"},"dispFirstSubmitDate":"2023-11-22","dispFirstPostDateStruct":{"date":"2024-08-30","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-08-06","lastUpdatePostDateStruct":{"date":"2024-08-30","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Bavarian Nordic","class":"INDUSTRY"},"collaborators":[{"name":"Emergent BioSolutions","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The goal of this multi-center, randomized, double blind, placebo controlled study is to evaluate the safety and immunogenicity of PXVX0317 (CHIKV VLP vaccine) in healthy adult and adolescent subjects.","detailedDescription":"Coprimary Objectives:\n\n1. To evaluate the safety of PXVX0317 (CHIKV VLP vaccine) in healthy adult and adolescent participants 12 to \\<65 years of age.\n2. To compare the anti-CHIKV serum neutralizing antibody (SNA) response to PXVX0317 (CHIKV VLP vaccine) and placebo at Day 22, as measured by geometric mean titer (GMT) and clinically relevant difference in seroresponse rate (PXVX0317 minus placebo).\n3. To demonstrate the consistency of the anti-CHIKV SNA response across three consecutively manufactured lots of PXVX0317 (CHIKV VLP vaccine) at Day 22 as measured by GMT.\n\nSecondary Objectives:\n\n1. To compare the anti-CHIKV SNA response to PXVX0317 (CHIKV VLP vaccine) and placebo at Day 15, Day 183, and Day 8 as measured by GMT and seroresponse rate.\n2. To compare the GMT fold increase in anti-CHIKV SNA response and number and percentage of participants with an anti-CHIKV SNA titer ≥15 and 4-fold rise over baseline, both at Day 8, 15, 22, and 183."},"conditionsModule":{"conditions":["Chikungunya Virus"],"keywords":["Chikungunya","VLP","PXVX0317","vaccine","immunogenicity","CHIKV"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","interventionModelDescription":"Participants will be randomized in a 2:2:2:1 ratio within each age stratum (12 to \\<18, 18 to \\<46, and 46 to \\<65). This study will be conducted in the US, using up to 50 sites.","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"TRIPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR"]}},"enrollmentInfo":{"count":3258,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Group 1","type":"EXPERIMENTAL","description":"Group 1 - PXVX0317 lot A (Lot 104)","interventionNames":["Biological: CHIKV VLP/adjuvant"]},{"label":"Group 2","type":"EXPERIMENTAL","description":"Group 2 - PXVX0317 lot B (Lot 105)","interventionNames":["Biological: CHIKV VLP/adjuvant"]},{"label":"Group 3","type":"EXPERIMENTAL","description":"Group 3 - PXVX0317 lot C (Lot 106)","interventionNames":["Biological: CHIKV VLP/adjuvant"]},{"label":"Group 4","type":"PLACEBO_COMPARATOR","description":"Group 4 - Placebo","interventionNames":["Biological: Placebo"]}],"interventions":[{"type":"BIOLOGICAL","name":"CHIKV VLP/adjuvant","description":"CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant 2%","armGroupLabels":["Group 1","Group 2","Group 3"]},{"type":"BIOLOGICAL","name":"Placebo","description":"Placebo is comprised of formulation buffer","armGroupLabels":["Group 4"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Incidence of Solicited Adverse Events (AE)","description":"Incidence of solicited AEs through Day 8 for PXVX0317 (CHIKV VLP vaccine) and placebo for all age strata combined (safety population).","timeFrame":"7 days post-vaccination"},{"measure":"Incidence of Unsolicited AEs","description":"Incidence of unsolicited AEs through Day 29 for PXVX0317 (CHIKV VLP vaccine) and placebo for all age strata combined (safety population).","timeFrame":"28 days post-vaccination"},{"measure":"Incidence of Adverse Events of Special Interest (AESI)","description":"Incidence of AESIs, through Day 183 for PXVX0317 (CHIKV VLP vaccine) and placebo for all age strata combined (safety population).","timeFrame":"182 days post-vaccination"},{"measure":"Incidence of Medically Attended Adverse Event (MAAE)","description":"Incidence of MAAEs through Day 183 for PXVX0317 (CHIKV VLP vaccine) and placebo for all age strata combined (safety population).","timeFrame":"182 days post-vaccination"},{"measure":"Incidence of Serious Adverse Event (SAE)","description":"Incidence of SAEs through Day 183 for PXVX0317 (CHIKV VLP vaccine) and placebo for all age strata combined (safety population).","timeFrame":"182 days post-vaccination"},{"measure":"Anti-CHIKV Serum Neutralizing Antibody (SNA) Seroresponse Rates at Day 22","description":"Anti-CHIKV SNA seroresponse rates for PXVX0317 (CHIKV VLP vaccine) and placebo, difference (PXVX0317 minus placebo), and associated 95% confidence interval (CI) at Day 22 for the immunogenicity evaluable population (IEP), all age strata combined.","timeFrame":"21 days post-vaccination"},{"measure":"Anti-CHIKV Serum Neutralizing Antibody (SNA) Seroresponse Rates at Day 22 (Data Reported Per Arm)","description":"Anti-CHIKV SNA seroresponse rates and associated 95% confidence interval for PXVX0317 (CHIKV VLP vaccine) and placebo at Day 22 for the immunogenicity evaluable population (IEP), all age strata combined.","timeFrame":"21 days post-vaccination"},{"measure":"Anti-CHIKV SNA Geometric Mean Titers (GMT) at Day 22","description":"Anti-CHIKV SNA GMTs and associated 95% CIs at Day 22 for PXVX0317 (CHIKV VLP vaccine) and placebo for the IEP, all age strata combined.","timeFrame":"21 days post-vaccination"},{"measure":"Anti-CHIKV SNA Geometric Mean Titers (GMT) at Day 22 (Data Reported Per Arm - All Age Strata)","description":"Anti-CHIKV SNA GMTs and associated 95% CIs at Day 22 for PXVX0317 (CHIKV VLP vaccine) and placebo for the IEP, all age strata combined.","timeFrame":"21 days post-vaccination"},{"measure":"Anti-CHIKV SNA Geometric Mean Titers (GMT) at Day 22 (for Lot Comparison)","description":"Anti-CHIKV SNA GMTs and associated 95% CIs between all three pairs of PXVX0317 (CHIKV VLP vaccine) lots (104:105, 104:106, 105:106) in adults 18 to \\<46 years of age in the IEP at Day 22. Placebo group 4 is not relevant for this lot-to-lot consistency analysis.\n\nReported GMT estimates and 95% CIs are derived from an ANOVA model that includes site and product lot as fixed effects assuming normality of log titers.","timeFrame":"21 days post-vaccination"},{"measure":"Anti-CHIKV SNA Geometric Mean Titers (GMT) at Day 22 (Data Reported Per Arm - Adults 18 to <46)","description":"Anti-CHIKV SNA GMTs and associated 95% CIs for PXVX0317 (CHIKV VLP vaccine) and placebo in adults 18 to \\<46 years of age in the IEP at Day 22.","timeFrame":"21 days post-vaccination"}],"secondaryOutcomes":[{"measure":"Anti-CHIKV SNA Seroresponse Rates at Days 15, 183, and 8","description":"Anti-CHIKV SNA seroresponse rates for PXVX0317 (CHIKV VLP vaccine) and placebo, difference (PXVX0317 minus placebo), and associated 95% CIs at Day 15, Day 183, and Day 8, in that order, for the IEP, all age strata combined.\n\nNumber analyzed is number of participants with a sample result available at the indicated visit.","timeFrame":"Day 15, 183, and 8 (14, 182, and 7 days post-vaccination, respectively)"},{"measure":"Anti-CHIKV SNA Seroresponse Rates at Days 15, 183, and 8 (Data Reported Per Arm)","description":"Anti-CHIKV SNA seroresponse rates and associated 95% CIs for PXVX0317 (CHIKV VLP vaccine) and placebo at Day 15, Day 183, and Day 8, in that order, for the IEP, all age strata combined.\n\nNumber analyzed is number of participants with a sample result available at the indicated visit.","timeFrame":"Day 15, 183, and 8 (14, 182, and 7 days post-vaccination, respectively)"},{"measure":"Anti-CHIKV SNA Geometric Mean Titers (GMTs) at Days 8, 15, and 183","description":"Anti-CHIKV SNA GMTs with associated 95% CIs at Day 8, Day 15, and Day 183 for PXVX0317 (CHIKV VLP vaccine) and placebo for the IEP, all age strata combined.\n\nNumber analyzed is number of participants with a sample result available at the indicated visit.","timeFrame":"Day 8, 15, and 183 (7, 14, and 182 days post-vaccination, respectively)"},{"measure":"Anti-CHIKV SNA Geometric Mean Titers (GMTs) at Days 8, 15, and 183 (Data Reported Per Arm)","description":"Anti-CHIKV SNA GMTs with associated 95% CIs at Day 8, Day 15, and Day 183 for PXVX0317 (CHIKV VLP vaccine) and placebo for the IEP, all age strata combined.\n\nNumber analyzed is number of participants with a sample result available at the indicated visit","timeFrame":"Day 8, 15, and 183 (7, 14, and 182 days post-vaccination, respectively)"},{"measure":"Geometric Mean Fold Increase (GMFI) in Anti-CHIKV SNA Titers From Day 1 to Days 8, 15, 22, and 183","description":"Geometric mean fold increase (GMFI) in anti-CHIKV SNA titers from Day 1 to Day 8, Day 15, Day 22, and Day 183 for the IEP for all age strata combined.\n\nFold rise in geometric mean titer is the ratio of the post-baseline value to the baseline value (e.g. number of 2 represents a post-baseline doubling of geometric mean titer).\n\nNumber analyzed is number of participants with a sample result available at both Day 1 and the indicated visit.","timeFrame":"Day 8, 15, 22, and 183 (7,14, 21, and 182 days post-vaccination, respectively)"},{"measure":"Geometric Mean Fold Increase (GMFI) in Anti-CHIKV SNA Titers From Day 1 to Days 8, 15, 22, and 183 (Data Reported Per Arm)","description":"Geometric mean fold increase (GMFI) in anti-CHIKV SNA titers from Day 1 to Day 8, Day 15, Day 22, and Day 183 for the IEP for all age strata combined.\n\nFold rise in geometric mean titer is the ratio of the post-baseline value to the baseline value (e.g. number of 2 represents a post-baseline doubling of geometric mean titer).\n\nNumber analyzed is number of participants with a sample result available at both Day 1 and the indicated visit.","timeFrame":"Day 8, 15, 22, and 183 (7,14, 21, and 182 days post-vaccination, respectively)"},{"measure":"Number and Percentage of Participants With Anti-CHIKV SNA Titer ≥15 and 4-fold Rise Over Baseline at Days 8, 15, 22, and 183","description":"Number and percentage of participants with anti-CHIKV SNA titers ≥15 and 4-fold rise over baseline at Day 8, Day 15, Day 22, and Day 183 for the IEP for all age strata combined.\n\nNumber analyzed is number of participants with a sample result available at the indicated visit.","timeFrame":"Day 8, 15, 22, and 183 (7,14, 21, and 182 days post-vaccination, respectively)"},{"measure":"Number and Percentage of Participants With Anti-CHIKV SNA Titer ≥15 and 4-fold Rise Over Baseline at Days 8, 15, 22, and 183 (Data Reported Per Arm)","description":"Number and percentage of participants with anti-CHIKV SNA titers ≥15 and 4-fold rise over baseline at Day 8, Day 15, Day 22, and Day 183 for the IEP for all age strata combined.\n\nNumber analyzed is number of participants with a sample result available at the indicated visit.","timeFrame":"Day 8, 15, 22, and 183 (7,14, 21, and 182 days post-vaccination, respectively)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Able and willing to provide informed consent (and assent, as applicable) voluntarily signed by participant (and guardian, as applicable).\n* Males or females, 12 to \\<65 years of age.\n* Generally healthy, in the opinion of the investigator, based on medical history, physical examination, and screening laboratory assessments.\n* Women who are either: (i) Not of childbearing potential (CBP): pre-menarche, surgically sterile (at least six weeks post bilateral tubal ligation, bilateral oophorectomy or hysterectomy), or postmenopausal (defined as a history of ≥12 consecutive months without menses prior to randomization in the absence of other pathologic or physiologic causes, following cessation of exogenous sex-hormonal treatment) or (ii) Meeting all the below criteria: Negative serum pregnancy test at screening visit, Negative urine pregnancy test immediately prior to dosing at Day 1, Using an acceptable method of contraception (if women of CBP) for the duration of participation, such as hormonal contraceptives (eg, implants, pills, patches) initiated ≥30 days prior to dosing, intrauterine device (IUD) inserted ≥30 days prior to dosing, double barrier type of birth control (male condom with female diaphragm, male condom with cervical cap), Abstinence is acceptable only for adolescents (12 to \\<18 years old) who are not sexually active.\n\nExclusion Criteria:\n\n* Currently pregnant, breastfeeding, or planning to become pregnant during the study.\n* Body Mass Index (BMI) ≥35 kg/m2.\n* Positive laboratory evidence of current infection with human immunodeficiency virus (HIV-1, HIV-2), hepatitis C virus (HCV) or hepatitis B virus (HBV).\n* History of severe allergic reaction or anaphylaxis to any component of the vaccine.\n* History of any known congenital or acquired immunodeficiency that could impact response to vaccination (eg, leukemia, lymphoma, generalized malignancy, functional or anatomic asplenia, alcoholic cirrhosis).\n* Prior receipt or anticipated use of systemic immunomodulatory or immunosuppressive medications from six months prior to screening through Day 22. Note: For systemic corticosteroids, use at a dose or equivalent dose of 20 mg of prednisone daily for 14 days or more within three months of screening through Day 22 is exclusionary. The use of inhaled, intranasal, topical, ocular, or intraocular steroids is allowed.\n* Receipt or anticipated receipt of blood or blood-derived products from 90 days prior to screening through Day 22.\n* Acute disease within the last 14 days (participants with an acute mild febrile illness can be considered for a deferral of vaccination two weeks after the illness has resolved and treatment has been completed).\n* Clinically significant cardiac, pulmonary, rheumatologic, or other chronic disease, in the opinion of the investigator. This may include chronic illness requiring hospitalization in the last 30 days prior to screening.\n* Enrollment in an interventional study and/or receipt of another investigational product from 30 days prior to screening through the duration of study participation.\n* Receipt or anticipated receipt of any vaccine from 30 days prior to Day 1 through Day 22.\n* Evidence of substance abuse that, in the opinion of the investigator, could adversely impact the participant's participation or the conduct of the study.\n* Prior receipt of an investigational CHIKV vaccine/product.\n* Any other medical condition that, in the opinion of the investigator, could adversely impact the participant's participation or the conduct of the study.","healthyVolunteers":true,"sex":"ALL","minimumAge":"12 Years","maximumAge":"64 Years","stdAges":["CHILD","ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Patrick Ajiboye, MD","affiliation":"Bavarian Nordic","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Optimal Research, LLC","city":"Huntsville","state":"Alabama","zip":"35802","country":"United States","geoPoint":{"lat":34.7304,"lon":-86.58594}},{"facility":"Alliance for Multispecialty Research - Mobile","city":"Mobile","state":"Alabama","zip":"36608","country":"United States","geoPoint":{"lat":30.69436,"lon":-88.04305}},{"facility":"Alliance for Multispecialty Research, LLC","city":"Tempe","state":"Arizona","zip":"85281","country":"United States","geoPoint":{"lat":33.41477,"lon":-111.90931}},{"facility":"Velocity Clinical Research, Banning","city":"Banning","state":"California","zip":"92220","country":"United States","geoPoint":{"lat":33.92557,"lon":-116.87641}},{"facility":"Optimal Research, LLC","city":"San Diego","state":"California","zip":"92108","country":"United States","geoPoint":{"lat":32.71571,"lon":-117.16472}},{"facility":"Lynn Institute of the Rockies","city":"Colorado Springs","state":"Colorado","zip":"80918","country":"United States","geoPoint":{"lat":38.83388,"lon":-104.82136}},{"facility":"Jacksonville Center for Clinical Research","city":"Jacksonville","state":"Florida","zip":"32216","country":"United States","geoPoint":{"lat":30.33218,"lon":-81.65565}},{"facility":"Accel Research Sites-DeLand Clinical Research Unit","city":"Lake Mary","state":"Florida","zip":"32746","country":"United States","geoPoint":{"lat":28.75888,"lon":-81.31784}},{"facility":"Optimal Research, LLC","city":"Melbourne","state":"Florida","zip":"32934","country":"United States","geoPoint":{"lat":28.08363,"lon":-80.60811}},{"facility":"Suncoast Research Associates, LLC","city":"Miami","state":"Florida","zip":"33173","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Synexus Clinical Research US, Inc.","city":"Pinellas Park","state":"Florida","zip":"33781","country":"United States","geoPoint":{"lat":27.8428,"lon":-82.69954}},{"facility":"Palm Beach Research Center","city":"West Palm Beach","state":"Florida","zip":"33409","country":"United States","geoPoint":{"lat":26.71534,"lon":-80.05337}},{"facility":"Emory University School of Medicine","city":"Atlanta","state":"Georgia","zip":"30322","country":"United States","geoPoint":{"lat":33.749,"lon":-84.38798}},{"facility":"Velocity Clinical Research, Boise","city":"Meridian","state":"Idaho","zip":"83642","country":"United States","geoPoint":{"lat":43.61211,"lon":-116.39151}},{"facility":"Synexus Clinical Research US, Inc.","city":"Chicago","state":"Illinois","zip":"60602","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"facility":"Optimal Research LLC","city":"Peoria","state":"Illinois","zip":"61614","country":"United States","geoPoint":{"lat":40.69365,"lon":-89.58899}},{"facility":"Johnson County ClinTrials","city":"Lenexa","state":"Kansas","zip":"66219","country":"United States","geoPoint":{"lat":38.95362,"lon":-94.73357}},{"facility":"Alliance for Multispecialty Research, LLC","city":"Newton","state":"Kansas","zip":"67114","country":"United States","geoPoint":{"lat":38.04668,"lon":-97.34504}},{"facility":"Alliance for Multispecialty Research - Wichita East","city":"Wichita","state":"Kansas","zip":"67207","country":"United States","geoPoint":{"lat":37.69224,"lon":-97.33754}},{"facility":"Alliance for Multispecialty Research, LLC","city":"Lexington","state":"Kentucky","zip":"40509","country":"United States","geoPoint":{"lat":37.98869,"lon":-84.47772}},{"facility":"Alliance for Multispecialty Research, LLC","city":"New Orleans","state":"Louisiana","zip":"70119","country":"United States","geoPoint":{"lat":29.95465,"lon":-90.07507}},{"facility":"Optimal Research, LLC","city":"Rockville","state":"Maryland","zip":"20850","country":"United States","geoPoint":{"lat":39.084,"lon":-77.15276}},{"facility":"Alliance for Multispecialty Research - Kansas City","city":"Kansas City","state":"Missouri","zip":"64114","country":"United States","geoPoint":{"lat":39.09973,"lon":-94.57857}},{"facility":"Saint Louis University","city":"St Louis","state":"Missouri","zip":"63104","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"Synexus Clinical Research US, Inc.","city":"St Louis","state":"Missouri","zip":"63141","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"Wr-Crcn, Llc","city":"Las Vegas","state":"Nevada","zip":"89106","country":"United States","geoPoint":{"lat":36.17497,"lon":-115.13722}},{"facility":"Alliance for Multispecialty Research, LLC.","city":"Las Vegas","state":"Nevada","zip":"89119","country":"United States","geoPoint":{"lat":36.17497,"lon":-115.13722}},{"facility":"Rochester Clinical Research, Inc.","city":"Rochester","state":"New York","zip":"14609","country":"United States","geoPoint":{"lat":43.15478,"lon":-77.61556}},{"facility":"M3 Wake Research, Inc","city":"Raleigh","state":"North Carolina","zip":"27612","country":"United States","geoPoint":{"lat":35.7721,"lon":-78.63861}},{"facility":"Trial Management Associates, LLC","city":"Wilmington","state":"North Carolina","zip":"28403","country":"United States","geoPoint":{"lat":34.23556,"lon":-77.94604}},{"facility":"Cincinnati Children's Hospital Medical Center - The Gamble Vaccine Research Center","city":"Cincinnati","state":"Ohio","zip":"45229","country":"United States","geoPoint":{"lat":39.12711,"lon":-84.51439}},{"facility":"Velocity Clinical Rsearch, Inc.","city":"Cleveland","state":"Ohio","zip":"44122","country":"United States","geoPoint":{"lat":41.4995,"lon":-81.69541}},{"facility":"Aventiv Research Inc.","city":"Columbus","state":"Ohio","zip":"43213","country":"United States","geoPoint":{"lat":39.96118,"lon":-82.99879}},{"facility":"Lynn Institute of Norman","city":"Norman","state":"Oklahoma","zip":"73072","country":"United States","geoPoint":{"lat":35.22257,"lon":-97.43948}},{"facility":"Lynn Health Science Institute","city":"Oklahoma City","state":"Oklahoma","zip":"73112","country":"United States","geoPoint":{"lat":35.46756,"lon":-97.51643}},{"facility":"Velocity Clinical Research, Medford","city":"Medford","state":"Oregon","zip":"97504","country":"United States","geoPoint":{"lat":42.32652,"lon":-122.87559}},{"facility":"Velocity Clinical Research-Providence","city":"East Greenwich","state":"Rhode Island","zip":"02818","country":"United States","geoPoint":{"lat":41.66038,"lon":-71.45589}},{"facility":"Synexus Clinical Research US, Inc.","city":"Anderson","state":"South Carolina","zip":"29621","country":"United States","geoPoint":{"lat":34.50344,"lon":-82.65013}},{"facility":"Coastal Carolina Research Center","city":"North Charleston","state":"South Carolina","zip":"29405","country":"United States","geoPoint":{"lat":32.85462,"lon":-79.97481}},{"facility":"Alliance for Multispecialty Research, LLC","city":"Knoxville","state":"Tennessee","zip":"37920","country":"United States","geoPoint":{"lat":35.96064,"lon":-83.92074}},{"facility":"Velocity Clinical Research, Austin","city":"Cedar Park","state":"Texas","zip":"78613","country":"United States","geoPoint":{"lat":30.5052,"lon":-97.82029}},{"facility":"Texas Center for Drug Development, Inc.","city":"Houston","state":"Texas","zip":"77081","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Research Your Health","city":"Plano","state":"Texas","zip":"75093","country":"United States","geoPoint":{"lat":33.01984,"lon":-96.69889}},{"facility":"BFHC Research","city":"San Antonio","state":"Texas","zip":"78249","country":"United States","geoPoint":{"lat":29.42412,"lon":-98.49363}},{"facility":"DM Clinical Research","city":"Tomball","state":"Texas","zip":"77375","country":"United States","geoPoint":{"lat":30.09716,"lon":-95.61605}},{"facility":"Advanced Clinical Research","city":"West Jordan","state":"Utah","zip":"84088","country":"United States","geoPoint":{"lat":40.60967,"lon":-111.9391}},{"facility":"Alliance for Multispecialty Research, LLC","city":"Norfolk","state":"Virginia","zip":"23502","country":"United States","geoPoint":{"lat":36.84681,"lon":-76.28522}}]},"referencesModule":{"references":[{"pmid":"40158526","type":"DERIVED","citation":"Richardson JS, Anderson DM, Mendy J, Tindale LC, Muhammad S, Loreth T, Tredo SR, Warfield KL, Ramanathan R, Caso JT, Jenkins VA, Ajiboye P, Bedell L; EBSI-CV-317-004 Study Group. Chikungunya virus virus-like particle vaccine safety and immunogenicity in adolescents and adults in the USA: a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2025 Apr 19;405(10487):1343-1352. doi: 10.1016/S0140-6736(25)00345-9. Epub 2025 Mar 27."},{"pmid":"39004524","type":"DERIVED","citation":"Miao Q, Nguyen W, Zhu J, Liu G, van Oers MM, Tang B, Yan K, Larcher T, Suhrbier A, Pijlman GP. A getah virus-like-particle vaccine provides complete protection from viremia and arthritis in wild-type mice. Vaccine. 2024 Nov 14;42(25):126136. doi: 10.1016/j.vaccine.2024.07.037. Epub 2024 Jul 14."},{"pmid":"35709798","type":"DERIVED","citation":"Bennett SR, McCarty JM, Ramanathan R, Mendy J, Richardson JS, Smith J, Alexander J, Ledgerwood JE, de Lame PA, Royalty Tredo S, Warfield KL, Bedell L. Safety and immunogenicity of PXVX0317, an aluminium hydroxide-adjuvanted chikungunya virus-like particle vaccine: a randomised, double-blind, parallel-group, phase 2 trial. Lancet Infect Dis. 2022 Sep;22(9):1343-1355. doi: 10.1016/S1473-3099(22)00226-2. Epub 2022 Jun 13."}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"resultsSection":{"participantFlowModule":{"recruitmentDetails":"This was a multicenter study conducted in the United States, using 47 sites. Healthy participants were enrolled in this study. Recruitment Period was from September 29, 2021 to October 06, 2022.","groups":[{"id":"FG000","title":"Group 1","description":"Group 1 - PXVX0317 lot A\n\nCHIKV VLP/adjuvant: CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant 2%"},{"id":"FG001","title":"Group 2","description":"Group 2 - PXVX0317 lot B\n\nCHIKV VLP/adjuvant: CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant 2%"},{"id":"FG002","title":"Group 3","description":"Group 3 - PXVX0317 lot C\n\nCHIKV VLP/adjuvant: CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant 2%"},{"id":"FG003","title":"Group 4","description":"Group 4 - Placebo\n\nPlacebo: Placebo is comprised of formulation buffer"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"919"},{"groupId":"FG001","numSubjects":"948"},{"groupId":"FG002","numSubjects":"927"},{"groupId":"FG003","numSubjects":"464"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"803"},{"groupId":"FG001","numSubjects":"837"},{"groupId":"FG002","numSubjects":"832"},{"groupId":"FG003","numSubjects":"430"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"116"},{"groupId":"FG001","numSubjects":"111"},{"groupId":"FG002","numSubjects":"95"},{"groupId":"FG003","numSubjects":"34"}]}],"dropWithdraws":[{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"65"},{"groupId":"FG001","numSubjects":"70"},{"groupId":"FG002","numSubjects":"58"},{"groupId":"FG003","numSubjects":"23"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"45"},{"groupId":"FG001","numSubjects":"30"},{"groupId":"FG002","numSubjects":"27"},{"groupId":"FG003","numSubjects":"7"}]},{"type":"Sponsor Decision","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"Subject moved","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"5"},{"groupId":"FG003","numSubjects":"2"}]},{"type":"Withdrawal by parent","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"Subject was deployed","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"Subject left site without receiving dose","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"Subject incarcerated","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"}]},{"type":"Noncompliance (protocol, study, visits, e-diary, etc.)","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"1"}]},{"type":"Subject missed last visit (Day 183)","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Group 1","description":"Group 1 - PXVX0317 lot 104\n\nCHIKV VLP/adjuvant: CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant 2%"},{"id":"BG001","title":"Group 2","description":"Group 2 - PXVX0317 lot 105\n\nCHIKV VLP/adjuvant: CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant 2%"},{"id":"BG002","title":"Group 3","description":"Group 3 - PXVX0317 lot 106\n\nCHIKV VLP/adjuvant: CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant 2%"},{"id":"BG003","title":"Group 4","description":"Group 4 - Placebo\n\nPlacebo: Placebo is comprised of formulation buffer"},{"id":"BG004","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"919"},{"groupId":"BG001","value":"948"},{"groupId":"BG002","value":"927"},{"groupId":"BG003","value":"464"},{"groupId":"BG004","value":"3258"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"39","spread":"14.4"},{"groupId":"BG001","value":"38","spread":"14.3"},{"groupId":"BG002","value":"39","spread":"14.0"},{"groupId":"BG003","value":"39","spread":"14.4"},{"groupId":"BG004","value":"39","spread":"14.3"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"452"},{"groupId":"BG001","value":"506"},{"groupId":"BG002","value":"478"},{"groupId":"BG003","value":"231"},{"groupId":"BG004","value":"1667"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"467"},{"groupId":"BG001","value":"442"},{"groupId":"BG002","value":"449"},{"groupId":"BG003","value":"233"},{"groupId":"BG004","value":"1591"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"165"},{"groupId":"BG001","value":"166"},{"groupId":"BG002","value":"175"},{"groupId":"BG003","value":"71"},{"groupId":"BG004","value":"577"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"735"},{"groupId":"BG001","value":"760"},{"groupId":"BG002","value":"731"},{"groupId":"BG003","value":"379"},{"groupId":"BG004","value":"2605"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"19"},{"groupId":"BG001","value":"22"},{"groupId":"BG002","value":"21"},{"groupId":"BG003","value":"14"},{"groupId":"BG004","value":"76"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"13"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"32"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"26"},{"groupId":"BG001","value":"30"},{"groupId":"BG002","value":"23"},{"groupId":"BG003","value":"16"},{"groupId":"BG004","value":"95"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"10"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"190"},{"groupId":"BG001","value":"175"},{"groupId":"BG002","value":"169"},{"groupId":"BG003","value":"89"},{"groupId":"BG004","value":"623"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"663"},{"groupId":"BG001","value":"693"},{"groupId":"BG002","value":"687"},{"groupId":"BG003","value":"341"},{"groupId":"BG004","value":"2384"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"23"},{"groupId":"BG001","value":"32"},{"groupId":"BG002","value":"23"},{"groupId":"BG003","value":"8"},{"groupId":"BG004","value":"86"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"12"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"28"}]}]}]},{"title":"Height","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"cm","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"171.4","spread":"10.03"},{"groupId":"BG001","value":"170.4","spread":"9.55"},{"groupId":"BG002","value":"170.7","spread":"10.02"},{"groupId":"BG003","value":"171.2","spread":"9.97"},{"groupId":"BG004","value":"170.9","spread":"9.89"}]}]}]},{"title":"Weight","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"kg","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"78.5","spread":"16.50"},{"groupId":"BG001","value":"78.4","spread":"16.08"},{"groupId":"BG002","value":"78.3","spread":"16.42"},{"groupId":"BG003","value":"77.6","spread":"16.42"},{"groupId":"BG004","value":"78.3","spread":"16.34"}]}]}]},{"title":"Body Mass Index (BMI)","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"kg/m^2","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"26.63","spread":"4.579"},{"groupId":"BG001","value":"26.89","spread":"4.480"},{"groupId":"BG002","value":"26.73","spread":"4.499"},{"groupId":"BG003","value":"26.38","spread":"4.570"},{"groupId":"BG004","value":"26.70","spread":"4.527"}]}]}]},{"title":"Baseline Anti-CHIKV SNA Serostatus","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"Negative (<LLOQ)","categories":[{"measurements":[{"groupId":"BG000","value":"894"},{"groupId":"BG001","value":"925"},{"groupId":"BG002","value":"906"},{"groupId":"BG003","value":"458"},{"groupId":"BG004","value":"3183"}]}]},{"title":"Positive (>=LLOQ)","categories":[{"measurements":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"21"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"69"}]}]},{"title":"Missing","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"6"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Incidence of Solicited Adverse Events (AE)","description":"Incidence of solicited AEs through Day 8 for PXVX0317 (CHIKV VLP vaccine) and placebo for all age strata combined (safety population).","populationDescription":"The number of participants assessed is the number of safety population participants who completed a memory aid following the vaccination.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"7 days post-vaccination","groups":[{"id":"OG000","title":"Group 1","description":"Group 1 - PXVX0317 lot 104\n\nCHIKV VLP/adjuvant: CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant 2%"},{"id":"OG001","title":"Group 2","description":"Group 2 - PXVX0317 lot 105\n\nCHIKV VLP/adjuvant: CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant 2%"},{"id":"OG002","title":"Group 3","description":"Group 3 - PXVX0317 lot 106\n\nCHIKV VLP/adjuvant: CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant 2%"},{"id":"OG003","title":"Group 4","description":"Group 4 - Placebo\n\nPlacebo: Placebo is comprised of formulation buffer"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"906"},{"groupId":"OG001","value":"939"},{"groupId":"OG002","value":"920"},{"groupId":"OG003","value":"458"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"319"},{"groupId":"OG001","value":"373"},{"groupId":"OG002","value":"366"},{"groupId":"OG003","value":"124"}]}]}]},{"type":"PRIMARY","title":"Incidence of Unsolicited AEs","description":"Incidence of unsolicited AEs through Day 29 for PXVX0317 (CHIKV VLP vaccine) and placebo for all age strata combined (safety population).","populationDescription":"Safety population (vaccinated participants who provided safety assessment data), All ages pooled","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"28 days post-vaccination","groups":[{"id":"OG000","title":"Group 1","description":"Group 1 - PXVX0317 lot 104\n\nCHIKV VLP/adjuvant: CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant 2%"},{"id":"OG001","title":"Group 2","description":"Group 2 - PXVX0317 lot 105\n\nCHIKV VLP/adjuvant: CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant 2%"},{"id":"OG002","title":"Group 3","description":"Group 3 - PXVX0317 lot 106\n\nCHIKV VLP/adjuvant: CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant 2%"},{"id":"OG003","title":"Group 4","description":"Group 4 - Placebo\n\nPlacebo: Placebo is comprised of formulation buffer"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"918"},{"groupId":"OG001","value":"945"},{"groupId":"OG002","value":"927"},{"groupId":"OG003","value":"464"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"146"},{"groupId":"OG002","value":"155"},{"groupId":"OG003","value":"62"}]}]}]},{"type":"PRIMARY","title":"Incidence of Adverse Events of Special Interest (AESI)","description":"Incidence of AESIs, through Day 183 for PXVX0317 (CHIKV VLP vaccine) and placebo for all age strata combined (safety population).","populationDescription":"Safety population (vaccinated participants who provided safety assessment data), All ages pooled","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"182 days post-vaccination","groups":[{"id":"OG000","title":"Group 1","description":"Group 1 - PXVX0317 lot 104\n\nCHIKV VLP/adjuvant: CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant 2%"},{"id":"OG001","title":"Group 2","description":"Group 2 - PXVX0317 lot 105\n\nCHIKV VLP/adjuvant: CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant 2%"},{"id":"OG002","title":"Group 3","description":"Group 3 - PXVX0317 lot 106\n\nCHIKV VLP/adjuvant: CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant 2%"},{"id":"OG003","title":"Group 4","description":"Group 4 - Placebo\n\nPlacebo: Placebo is comprised of formulation buffer"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"918"},{"groupId":"OG001","value":"945"},{"groupId":"OG002","value":"927"},{"groupId":"OG003","value":"464"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"}]}]}]},{"type":"PRIMARY","title":"Incidence of Medically Attended Adverse Event (MAAE)","description":"Incidence of MAAEs through Day 183 for PXVX0317 (CHIKV VLP vaccine) and placebo for all age strata combined (safety population).","populationDescription":"Safety population (vaccinated participants who provided safety assessment data), All ages pooled","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"182 days post-vaccination","groups":[{"id":"OG000","title":"Group 1","description":"Group 1 - PXVX0317 lot 104\n\nCHIKV VLP/adjuvant: CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant 2%"},{"id":"OG001","title":"Group 2","description":"Group 2 - PXVX0317 lot 105\n\nCHIKV VLP/adjuvant: CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant 2%"},{"id":"OG002","title":"Group 3","description":"Group 3 - PXVX0317 lot 106\n\nCHIKV VLP/adjuvant: CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant 2%"},{"id":"OG003","title":"Group 4","description":"Group 4 - Placebo\n\nPlacebo: Placebo is comprised of formulation buffer"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"918"},{"groupId":"OG001","value":"945"},{"groupId":"OG002","value":"927"},{"groupId":"OG003","value":"464"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81"},{"groupId":"OG001","value":"83"},{"groupId":"OG002","value":"85"},{"groupId":"OG003","value":"42"}]}]}]},{"type":"PRIMARY","title":"Incidence of Serious Adverse Event (SAE)","description":"Incidence of SAEs through Day 183 for PXVX0317 (CHIKV VLP vaccine) and placebo for all age strata combined (safety population).","populationDescription":"Safety population (vaccinated participants who provided safety assessment data), All ages pooled","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"182 days post-vaccination","groups":[{"id":"OG000","title":"Group 1","description":"Group 1 - PXVX0317 lot 104\n\nCHIKV VLP/adjuvant: CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant 2%"},{"id":"OG001","title":"Group 2","description":"Group 2 - PXVX0317 lot 105\n\nCHIKV VLP/adjuvant: CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant 2%"},{"id":"OG002","title":"Group 3","description":"Group 3 - PXVX0317 lot 106\n\nCHIKV VLP/adjuvant: CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant 2%"},{"id":"OG003","title":"Group 4","description":"Group 4 - Placebo\n\nPlacebo: Placebo is comprised of formulation buffer"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"918"},{"groupId":"OG001","value":"945"},{"groupId":"OG002","value":"927"},{"groupId":"OG003","value":"464"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"1"}]}]}]},{"type":"PRIMARY","title":"Anti-CHIKV Serum Neutralizing Antibody (SNA) Seroresponse Rates at Day 22","description":"Anti-CHIKV SNA seroresponse rates for PXVX0317 (CHIKV VLP vaccine) and placebo, difference (PXVX0317 minus placebo), and associated 95% confidence interval (CI) at Day 22 for the immunogenicity evaluable population (IEP), all age strata combined.","populationDescription":"Immunogenicity evaluable population (randomized and vaccinated participants who provided an evaluable Day 22 anti-CHIKV SNA sample within the analysis window, had no measurable anti-CHIKV SNA titer at Day 1, and had no reason to be excluded as defined prior to unblinding). Groups 1, 2, and 3 are combined, as participants received same treatment of PXVX0317 (dose, adjuvant, schedule), with only difference being the lot of manufactured vaccine. Data is reported for PXVX0317 vaccinated vs. placebo.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants (rounded)","timeFrame":"21 days post-vaccination","groups":[{"id":"OG000","title":"PXVX0317","description":"All participants that received active PXVX0317 vaccine, regardless of the manufactured vaccine lot. This includes all participants contained in Group 1, Group 2, and Group 3.\n\nCHIKV VLP/adjuvant: CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant 2%"},{"id":"OG001","title":"Placebo","description":"Group 4 - Placebo\n\nPlacebo: Placebo is comprised of formulation buffer"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2559"},{"groupId":"OG001","value":"424"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.81","lowerLimit":"97.2","upperLimit":"98.3"},{"groupId":"OG001","value":"1.18","lowerLimit":"0.5","upperLimit":"2.7"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Day 22","nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","pValueComment":"p-value is from a two-sided chi-square test of equality of seroresponse percentages between groups. All 3 coprimary endpoints were required to be met for success, so no multiple comparisons were performed.","statisticalMethod":"Chi-squared","paramType":"Mean Difference (Final Values)","paramValue":"96.6","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"95.0","ciUpperLimit":"97.5","estimateComment":"Seroresponse rate difference is (PXVX0317 minus placebo)."}]},{"type":"PRIMARY","title":"Anti-CHIKV Serum Neutralizing Antibody (SNA) Seroresponse Rates at Day 22 (Data Reported Per Arm)","description":"Anti-CHIKV SNA seroresponse rates and associated 95% confidence interval for PXVX0317 (CHIKV VLP vaccine) and placebo at Day 22 for the immunogenicity evaluable population (IEP), all age strata combined.","populationDescription":"Immunogenicity evaluable population (randomized and vaccinated participants who provided an evaluable Day 22 anti-CHIKV SNA sample within the analysis window, had no measurable anti-CHIKV SNA titer at Day 1, and had no reason to be excluded as defined prior to unblinding).","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"21 days post-vaccination","groups":[{"id":"OG000","title":"Group 1","description":"Group 1 - PXVX0317 lot 104\n\nCHIKV VLP/adjuvant: CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant 2%"},{"id":"OG001","title":"Group 2","description":"Group 2 - PXVX0317 lot 105\n\nCHIKV VLP/adjuvant: CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant 2%"},{"id":"OG002","title":"Group 3","description":"Group 3 - PXVX0317 lot 106\n\nCHIKV VLP/adjuvant: CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant 2%"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"841"},{"groupId":"OG001","value":"860"},{"groupId":"OG002","value":"858"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.1","lowerLimit":"96.9","upperLimit":"98.8"},{"groupId":"OG001","value":"98.0","lowerLimit":"96.9","upperLimit":"98.8"},{"groupId":"OG002","value":"97.3","lowerLimit":"96.0","upperLimit":"98.2"}]}]}]},{"type":"PRIMARY","title":"Anti-CHIKV SNA Geometric Mean Titers (GMT) at Day 22","description":"Anti-CHIKV SNA GMTs and associated 95% CIs at Day 22 for PXVX0317 (CHIKV VLP vaccine) and placebo for the IEP, all age strata combined.","populationDescription":"Immunogenicity evaluable population (randomized and vaccinated participants who provided an evaluable Day 22 anti-CHIKV SNA sample within the analysis window, had no measurable anti-CHIKV SNA titer at Day 1, and had no reason to be excluded as defined prior to unblinding). Groups 1, 2, and 3 are combined, as participants received same treatment of PXVX0317 (dose, adjuvant, schedule), with only difference being the lot of manufactured vaccine. Data is reported for PXVX0317 vaccinated vs. placebo.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"21 days post-vaccination","groups":[{"id":"OG000","title":"PXVX0317","description":"All participants that received active PXVX0317 vaccine, regardless of the manufactured vaccine lot. This includes all participants contained in Group 1, Group 2, and Group 3.\n\nCHIKV VLP/adjuvant: CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant 2%"},{"id":"OG001","title":"Placebo","description":"Group 4 - Placebo\n\nPlacebo: Placebo is comprised of formulation buffer"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2559"},{"groupId":"OG001","value":"424"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1618","lowerLimit":"1522","upperLimit":"1720"},{"groupId":"OG001","value":"8","lowerLimit":"7","upperLimit":"9"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Day 22","nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","pValueComment":"All 3 coprimary endpoints were required to be met for success, so no multiple comparisons were performed.","statisticalMethod":"ANOVA","statisticalComment":"ANOVA model includes site and treatment group as fixed effects, assuming normality of log titers. p-value tests equivalence of group GMTs on log scale","paramType":"GMT Ratio","paramValue":"206","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"183","ciUpperLimit":"232","estimateComment":"Ratio of GMTs is (PXVX0317:placebo)."}]},{"type":"PRIMARY","title":"Anti-CHIKV SNA Geometric Mean Titers (GMT) at Day 22 (Data Reported Per Arm - All Age Strata)","description":"Anti-CHIKV SNA GMTs and associated 95% CIs at Day 22 for PXVX0317 (CHIKV VLP vaccine) and placebo for the IEP, all age strata combined.","populationDescription":"Immunogenicity evaluable population (randomized and vaccinated participants who provided an evaluable Day 22 anti-CHIKV SNA sample within the analysis window, had no measurable anti-CHIKV SNA titer at Day 1, and had no reason to be excluded as defined prior to unblinding).","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"21 days post-vaccination","groups":[{"id":"OG000","title":"Group 1","description":"Group 1 - PXVX0317 lot 104\n\nCHIKV VLP/adjuvant: CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant 2%"},{"id":"OG001","title":"Group 2","description":"Group 2 - PXVX0317 lot 105\n\nCHIKV VLP/adjuvant: CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant 2%"},{"id":"OG002","title":"Group 3","description":"Group 3 - PXVX0317 lot 106\n\nCHIKV VLP/adjuvant: CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant 2%"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"841"},{"groupId":"OG001","value":"860"},{"groupId":"OG002","value":"858"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1592","lowerLimit":"1458","upperLimit":"1739"},{"groupId":"OG001","value":"1640","lowerLimit":"1503","upperLimit":"1789"},{"groupId":"OG002","value":"1622","lowerLimit":"1486","upperLimit":"1771"}]}]}]},{"type":"PRIMARY","title":"Anti-CHIKV SNA Geometric Mean Titers (GMT) at Day 22 (for Lot Comparison)","description":"Anti-CHIKV SNA GMTs and associated 95% CIs between all three pairs of PXVX0317 (CHIKV VLP vaccine) lots (104:105, 104:106, 105:106) in adults 18 to \\<46 years of age in the IEP at Day 22. Placebo group 4 is not relevant for this lot-to-lot consistency analysis.\n\nReported GMT estimates and 95% CIs are derived from an ANOVA model that includes site and product lot as fixed effects assuming normality of log titers.","populationDescription":"Adults 18 to \\<46 years in Immunogenicity evaluable population (randomized and vaccinated participants who provided an evaluable Day 22 anti-CHIKV SNA sample within the analysis window, had no measurable anti-CHIKV SNA titer at Day 1, and had no reason to be excluded as defined prior to unblinding). Placebo group 4 does not apply for this PXVX0317 lot-to-lot consistency analysis.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titer","timeFrame":"21 days post-vaccination","groups":[{"id":"OG000","title":"Group 1","description":"Group 1 - PXVX0317 lot 104\n\nCHIKV VLP/adjuvant: CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant 2%"},{"id":"OG001","title":"Group 2","description":"Group 2 - PXVX0317 lot 105\n\nCHIKV VLP/adjuvant: CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant 2%"},{"id":"OG002","title":"Group 3","description":"Group 3 - PXVX0317 lot 106\n\nCHIKV VLP/adjuvant: CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant 2%"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"488"},{"groupId":"OG001","value":"498"},{"groupId":"OG002","value":"494"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1857","lowerLimit":"1641","upperLimit":"2101"},{"groupId":"OG001","value":"1887","lowerLimit":"1672","upperLimit":"2130"},{"groupId":"OG002","value":"1950","lowerLimit":"1724","upperLimit":"2207"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"EQUIVALENCE","nonInferiorityComment":"Success criterion was pairwise GMT ratios (104:105, 105:106, 104:106) each with a two-sided 95% CI within \\[0.667; 1.5\\].","paramType":"GMT Ratio","paramValue":"0.98","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.85","ciUpperLimit":"1.14","estimateComment":"All 3 coprimary endpoints were required to be met for success, so no multiple comparisons were performed. GMT estimates and 95% CIs are derived from an ANOVA model that includes site and product lot as fixed effects assuming normality of log titers."},{"groupIds":["OG001","OG002"],"nonInferiorityType":"EQUIVALENCE","nonInferiorityComment":"Success criterion was pairwise GMT ratios (104:105, 105:106, 104:106) each with a two-sided 95% CI within \\[0.667; 1.5\\].","paramType":"GMT Ratio","paramValue":"0.97","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.84","ciUpperLimit":"1.12","estimateComment":"All 3 coprimary endpoints were required to be met for success, so no multiple comparisons were performed. GMT estimates and 95% CIs are derived from an ANOVA model that includes site and product lot as fixed effects assuming normality of log titers."},{"groupIds":["OG000","OG002"],"nonInferiorityType":"EQUIVALENCE","nonInferiorityComment":"Success criterion was pairwise GMT ratios (104:105, 105:106, 104:106) each with a two-sided 95% CI within \\[0.667; 1.5\\].","paramType":"GMT Ratio","paramValue":"0.95","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.82","ciUpperLimit":"1.10","estimateComment":"All 3 coprimary endpoints were required to be met for success, so no multiple comparisons were performed. GMT estimates and 95% CIs are derived from an ANOVA model that includes site and product lot as fixed effects assuming normality of log titers."}]},{"type":"PRIMARY","title":"Anti-CHIKV SNA Geometric Mean Titers (GMT) at Day 22 (Data Reported Per Arm - Adults 18 to <46)","description":"Anti-CHIKV SNA GMTs and associated 95% CIs for PXVX0317 (CHIKV VLP vaccine) and placebo in adults 18 to \\<46 years of age in the IEP at Day 22.","populationDescription":"Adults 18 to \\<46 years in Immunogenicity evaluable population (randomized and vaccinated participants who provided an evaluable Day 22 anti-CHIKV SNA sample within the analysis window, had no measurable anti-CHIKV SNA titer at Day 1, and had no reason to be excluded as defined prior to unblinding).","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"21 days post-vaccination","groups":[{"id":"OG000","title":"Group 1","description":"Group 1 - PXVX0317 lot 104\n\nCHIKV VLP/adjuvant: CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant 2%"},{"id":"OG001","title":"Group 2","description":"Group 2 - PXVX0317 lot 105\n\nCHIKV VLP/adjuvant: CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant 2%"},{"id":"OG002","title":"Group 3","description":"Group 3 - PXVX0317 lot 106\n\nCHIKV VLP/adjuvant: CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant 2%"},{"id":"OG003","title":"Group 4","description":"Group 4 - Placebo\n\nPlacebo: Placebo is comprised of formulation buffer"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"488"},{"groupId":"OG001","value":"498"},{"groupId":"OG002","value":"494"},{"groupId":"OG003","value":"245"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1838","lowerLimit":"1638","upperLimit":"2063"},{"groupId":"OG001","value":"1866","lowerLimit":"1666","upperLimit":"2089"},{"groupId":"OG002","value":"1932","lowerLimit":"1721","upperLimit":"2169"},{"groupId":"OG003","value":"8","lowerLimit":"7","upperLimit":"10"}]}]}]},{"type":"SECONDARY","title":"Anti-CHIKV SNA Seroresponse Rates at Days 15, 183, and 8","description":"Anti-CHIKV SNA seroresponse rates for PXVX0317 (CHIKV VLP vaccine) and placebo, difference (PXVX0317 minus placebo), and associated 95% CIs at Day 15, Day 183, and Day 8, in that order, for the IEP, all age strata combined.\n\nNumber analyzed is number of participants with a sample result available at the indicated visit.","populationDescription":"Immunogenicity evaluable population (randomized and vaccinated participants who provided an evaluable Day 22 anti-CHIKV SNA sample within the analysis window, had no measurable anti-CHIKV SNA titer at Day 1, and had no reason to be excluded as defined prior to unblinding). Groups 1, 2, and 3 are combined, as participants received same treatment of PXVX0317 (dose, adjuvant, schedule), with only difference being the lot of manufactured vaccine. Data is reported for PXVX0317 vaccinated vs. placebo.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Day 15, 183, and 8 (14, 182, and 7 days post-vaccination, respectively)","groups":[{"id":"OG000","title":"PXVX0317","description":"All participants that received active PXVX0317 vaccine, regardless of the manufactured vaccine lot. This includes all participants contained in Group 1, Group 2, and Group 3.\n\nCHIKV VLP/adjuvant: CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant 2%"},{"id":"OG001","title":"Placebo","description":"Group 4 - Placebo\n\nPlacebo: Placebo is comprised of formulation buffer"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2559"},{"groupId":"OG001","value":"424"}]}],"classes":[{"title":"Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2434"},{"groupId":"OG001","value":"395"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"96.8","lowerLimit":"96.0","upperLimit":"97.4"},{"groupId":"OG001","value":"0.8","lowerLimit":"0.3","upperLimit":"2.2"}]}]},{"title":"Day 183","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2301"},{"groupId":"OG001","value":"401"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"85.5","lowerLimit":"84.0","upperLimit":"86.9"},{"groupId":"OG001","value":"1.5","lowerLimit":"0.7","upperLimit":"3.2"}]}]},{"title":"Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2510"},{"groupId":"OG001","value":"419"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"46.6","lowerLimit":"44.6","upperLimit":"48.5"},{"groupId":"OG001","value":"0.5","lowerLimit":"0.1","upperLimit":"1.7"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Day 15","nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","pValueComment":"Key secondary endpoints were tested hierarchically, such that each was only tested if all 3 coprimary endpoints and prior key secondary endpoints were met, so no multiple comparisons were performed.","statisticalMethod":"Chi-squared","statisticalComment":"p-value is from a two-sided chi-square test of equality of seroresponse percentages between groups.","paramType":"Mean Difference (Final Values)","paramValue":"96.0","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"94.3","ciUpperLimit":"96.8","estimateComment":"Seroresponse rate difference is (PXVX0317 minus placebo)."},{"groupIds":["OG000","OG001"],"groupDescription":"Day 183","nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","pValueComment":"Key secondary endpoints were tested hierarchically, such that each was only tested if all 3 coprimary endpoints and prior key secondary endpoints were met, so no multiple comparisons were performed.","statisticalMethod":"Chi-squared","statisticalComment":"p-value is from a two-sided chi-square test of equality of seroresponse percentages between groups.","paramType":"Mean Difference (Final Values)","paramValue":"84.0","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"81.7","ciUpperLimit":"85.6","estimateComment":"Seroresponse rate difference is (PXVX0317 minus placebo)."},{"groupIds":["OG000","OG001"],"groupDescription":"Day 8","nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","pValueComment":"Key secondary endpoints were tested hierarchically, such that each was only tested if all 3 coprimary endpoints and prior key secondary endpoints were met, so no multiple comparisons were performed.","statisticalMethod":"Chi-squared","statisticalComment":"p-value is from a two-sided chi-square test of equality of seroresponse percentages between groups.","paramType":"Mean Difference (Final Values)","paramValue":"46.1","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"43.8","ciUpperLimit":"48.1","estimateComment":"Seroresponse rate difference is (PXVX0317 minus placebo)."}]},{"type":"SECONDARY","title":"Anti-CHIKV SNA Seroresponse Rates at Days 15, 183, and 8 (Data Reported Per Arm)","description":"Anti-CHIKV SNA seroresponse rates and associated 95% CIs for PXVX0317 (CHIKV VLP vaccine) and placebo at Day 15, Day 183, and Day 8, in that order, for the IEP, all age strata combined.\n\nNumber analyzed is number of participants with a sample result available at the indicated visit.","populationDescription":"Immunogenicity evaluable population (randomized and vaccinated participants who provided an evaluable Day 22 anti-CHIKV SNA sample within the analysis window, had no measurable anti-CHIKV SNA titer at Day 1, and had no reason to be excluded as defined prior to unblinding).","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Day 15, 183, and 8 (14, 182, and 7 days post-vaccination, respectively)","groups":[{"id":"OG000","title":"Group 1","description":"Group 1 - PXVX0317 lot 104\n\nCHIKV VLP/adjuvant: CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant 2%"},{"id":"OG001","title":"Group 2","description":"Group 2 - PXVX0317 lot 105\n\nCHIKV VLP/adjuvant: CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant 2%"},{"id":"OG002","title":"Group 3","description":"Group 3 - PXVX0317 lot 106\n\nCHIKV VLP/adjuvant: CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant 2%"},{"id":"OG003","title":"Group 4","description":"Group 4 - Placebo\n\nPlacebo: Placebo is comprised of formulation buffer"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"841"},{"groupId":"OG001","value":"860"},{"groupId":"OG002","value":"858"},{"groupId":"OG003","value":"424"}]}],"classes":[{"title":"Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"800"},{"groupId":"OG001","value":"828"},{"groupId":"OG002","value":"806"},{"groupId":"OG003","value":"395"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"96.6","lowerLimit":"95.1","upperLimit":"97.7"},{"groupId":"OG001","value":"97.1","lowerLimit":"95.7","upperLimit":"98.0"},{"groupId":"OG002","value":"96.5","lowerLimit":"95.0","upperLimit":"97.6"},{"groupId":"OG003","value":"0.8","lowerLimit":"0.3","upperLimit":"2.2"}]}]},{"title":"Day 183","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"752"},{"groupId":"OG001","value":"772"},{"groupId":"OG002","value":"777"},{"groupId":"OG003","value":"401"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"84.6","lowerLimit":"81.8","upperLimit":"87.0"},{"groupId":"OG001","value":"85.9","lowerLimit":"83.2","upperLimit":"88.2"},{"groupId":"OG002","value":"86.0","lowerLimit":"83.4","upperLimit":"88.2"},{"groupId":"OG003","value":"1.5","lowerLimit":"0.7","upperLimit":"3.2"}]}]},{"title":"Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"827"},{"groupId":"OG001","value":"848"},{"groupId":"OG002","value":"835"},{"groupId":"OG003","value":"419"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"45.8","lowerLimit":"42.5","upperLimit":"49.2"},{"groupId":"OG001","value":"47.8","lowerLimit":"44.4","upperLimit":"51.1"},{"groupId":"OG002","value":"46.1","lowerLimit":"42.8","upperLimit":"49.5"},{"groupId":"OG003","value":"0.5","lowerLimit":"0.1","upperLimit":"1.7"}]}]}]},{"type":"SECONDARY","title":"Anti-CHIKV SNA Geometric Mean Titers (GMTs) at Days 8, 15, and 183","description":"Anti-CHIKV SNA GMTs with associated 95% CIs at Day 8, Day 15, and Day 183 for PXVX0317 (CHIKV VLP vaccine) and placebo for the IEP, all age strata combined.\n\nNumber analyzed is number of participants with a sample result available at the indicated visit.","populationDescription":"Immunogenicity evaluable population (randomized and vaccinated participants who provided an evaluable Day 22 anti-CHIKV SNA sample within the analysis window, had no measurable anti-CHIKV SNA titer at Day 1, and had no reason to be excluded as defined prior to unblinding). Groups 1, 2, and 3 are combined, as participants received same treatment of PXVX0317 (dose, adjuvant, schedule), with only difference being the lot of manufactured vaccine. Data is reported for PXVX0317 vaccinated vs. placebo.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"Day 8, 15, and 183 (7, 14, and 182 days post-vaccination, respectively)","groups":[{"id":"OG000","title":"PXVX0317","description":"All participants that received active PXVX0317 vaccine, regardless of the manufactured vaccine lot. This includes all participants contained in Group 1, Group 2, and Group 3.\n\nCHIKV VLP/adjuvant: CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant 2%"},{"id":"OG001","title":"Placebo","description":"Group 4 - Placebo\n\nPlacebo: Placebo is comprised of formulation buffer"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2559"},{"groupId":"OG001","value":"424"}]}],"classes":[{"title":"Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2510"},{"groupId":"OG001","value":"419"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"93","lowerLimit":"87","upperLimit":"100"},{"groupId":"OG001","value":"7","lowerLimit":"6","upperLimit":"8"}]}]},{"title":"Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2434"},{"groupId":"OG001","value":"395"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1096","lowerLimit":"1029","upperLimit":"1167"},{"groupId":"OG001","value":"8","lowerLimit":"7","upperLimit":"9"}]}]},{"title":"Day 183","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2301"},{"groupId":"OG001","value":"401"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"338","lowerLimit":"318","upperLimit":"358"},{"groupId":"OG001","value":"8","lowerLimit":"7","upperLimit":"9"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Day 8","nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","statisticalMethod":"ANOVA","statisticalComment":"ANOVA model includes site and treatment group as fixed effects, assuming normality of log titers. p-value tests equivalence of group GMTs on log scale","paramType":"GMT Ratio","paramValue":"13","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"11","ciUpperLimit":"14","estimateComment":"Ratio of GMTs is (PXVX0317:placebo)"},{"groupIds":["OG000","OG001"],"groupDescription":"Day 15","nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","statisticalMethod":"ANOVA","statisticalComment":"ANOVA model includes site and treatment group as fixed effects, assuming normality of log titers. p-value tests equivalence of group GMTs on log scale","paramType":"GMT Ratio","paramValue":"144","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"128","ciUpperLimit":"162","estimateComment":"Ratio of GMTs is (PXVX0317:placebo)"},{"groupIds":["OG000","OG001"],"groupDescription":"Day 183","nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","statisticalMethod":"ANOVA","statisticalComment":"ANOVA model includes site and treatment group as fixed effects, assuming normality of log titers. p-value tests equivalence of group GMTs on log scale","paramType":"GMT Ratio","paramValue":"41","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"37","ciUpperLimit":"46","estimateComment":"Ratio of GMTs is (PXVX0317:placebo)"}]},{"type":"SECONDARY","title":"Anti-CHIKV SNA Geometric Mean Titers (GMTs) at Days 8, 15, and 183 (Data Reported Per Arm)","description":"Anti-CHIKV SNA GMTs with associated 95% CIs at Day 8, Day 15, and Day 183 for PXVX0317 (CHIKV VLP vaccine) and placebo for the IEP, all age strata combined.\n\nNumber analyzed is number of participants with a sample result available at the indicated visit","populationDescription":"Immunogenicity evaluable population (randomized and vaccinated participants who provided an evaluable Day 22 anti-CHIKV SNA sample within the analysis window, had no measurable anti-CHIKV SNA titer at Day 1, and had no reason to be excluded as defined prior to unblinding).","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"Day 8, 15, and 183 (7, 14, and 182 days post-vaccination, respectively)","groups":[{"id":"OG000","title":"Group 1","description":"Group 1 - PXVX0317 lot 104\n\nCHIKV VLP/adjuvant: CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant 2%"},{"id":"OG001","title":"Group 2","description":"Group 2 - PXVX0317 lot 105\n\nCHIKV VLP/adjuvant: CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant 2%"},{"id":"OG002","title":"Group 3","description":"Group 3 - PXVX0317 lot 106\n\nCHIKV VLP/adjuvant: CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant 2%"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"841"},{"groupId":"OG001","value":"860"},{"groupId":"OG002","value":"858"}]}],"classes":[{"title":"Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"827"},{"groupId":"OG001","value":"848"},{"groupId":"OG002","value":"835"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"90","lowerLimit":"82","upperLimit":"99"},{"groupId":"OG001","value":"97","lowerLimit":"88","upperLimit":"106"},{"groupId":"OG002","value":"93","lowerLimit":"85","upperLimit":"103"}]}]},{"title":"Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"800"},{"groupId":"OG001","value":"828"},{"groupId":"OG002","value":"806"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1073","lowerLimit":"981","upperLimit":"1173"},{"groupId":"OG001","value":"1112","lowerLimit":"1019","upperLimit":"1215"},{"groupId":"OG002","value":"1102","lowerLimit":"1007","upperLimit":"1206"}]}]},{"title":"Day 183","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"752"},{"groupId":"OG001","value":"772"},{"groupId":"OG002","value":"777"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"331","lowerLimit":"304","upperLimit":"360"},{"groupId":"OG001","value":"342","lowerLimit":"315","upperLimit":"372"},{"groupId":"OG002","value":"340","lowerLimit":"313","upperLimit":"370"}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Fold Increase (GMFI) in Anti-CHIKV SNA Titers From Day 1 to Days 8, 15, 22, and 183","description":"Geometric mean fold increase (GMFI) in anti-CHIKV SNA titers from Day 1 to Day 8, Day 15, Day 22, and Day 183 for the IEP for all age strata combined.\n\nFold rise in geometric mean titer is the ratio of the post-baseline value to the baseline value (e.g. number of 2 represents a post-baseline doubling of geometric mean titer).\n\nNumber analyzed is number of participants with a sample result available at both Day 1 and the indicated visit.","populationDescription":"Immunogenicity evaluable population (randomized and vaccinated participants who provided an evaluable Day 22 anti-CHIKV SNA sample within the analysis window, had no measurable anti-CHIKV SNA titer at Day 1, and had no reason to be excluded as defined prior to unblinding). Groups 1, 2, and 3 are combined, as participants received same treatment of PXVX0317 (dose, adjuvant, schedule), with only difference being the lot of manufactured vaccine. Data is reported for PXVX0317 vaccinated vs. placebo.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Fold rise from baseline","timeFrame":"Day 8, 15, 22, and 183 (7,14, 21, and 182 days post-vaccination, respectively)","groups":[{"id":"OG000","title":"PXVX0317","description":"All participants that received active PXVX0317 vaccine, regardless of the manufactured vaccine lot. This includes all participants contained in Group 1, Group 2, and Group 3.\n\nCHIKV VLP/adjuvant: CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant 2%"},{"id":"OG001","title":"Placebo","description":"Group 4 - Placebo\n\nPlacebo: Placebo is comprised of formulation buffer"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2559"},{"groupId":"OG001","value":"424"}]}],"classes":[{"title":"Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2510"},{"groupId":"OG001","value":"419"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12.5","lowerLimit":"11.6","upperLimit":"13.3"},{"groupId":"OG001","value":"1.0","lowerLimit":"0.9","upperLimit":"1.1"}]}]},{"title":"Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2434"},{"groupId":"OG001","value":"395"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"146.1","lowerLimit":"137.2","upperLimit":"155.6"},{"groupId":"OG001","value":"1.0","lowerLimit":"0.9","upperLimit":"1.1"}]}]},{"title":"Day 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2559"},{"groupId":"OG001","value":"424"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"215.7","lowerLimit":"203.0","upperLimit":"229.3"},{"groupId":"OG001","value":"1.1","lowerLimit":"0.9","upperLimit":"1.2"}]}]},{"title":"Day 183","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2301"},{"groupId":"OG001","value":"401"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"45.0","lowerLimit":"42.4","upperLimit":"47.8"},{"groupId":"OG001","value":"1.1","lowerLimit":"1.0","upperLimit":"1.2"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Day 8","nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","pValueComment":"GMFI estimates and 95% CIs are based on t-statistics assuming a normal distribution of the log fold increase in titer. p-value tests equality of log fold increase in titer between groups.","statisticalMethod":"t-test, 2 sided"},{"groupIds":["OG000","OG001"],"groupDescription":"Day 15","nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","pValueComment":"GMFI estimates and 95% CIs are based on t-statistics assuming a normal distribution of the log fold increase in titer. p-value tests equality of log fold increase in titer between groups.","statisticalMethod":"t-test, 2 sided"},{"groupIds":["OG000","OG001"],"groupDescription":"Day 22","nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","pValueComment":"GMFI estimates and 95% CIs are based on t-statistics assuming a normal distribution of the log fold increase in titer. p-value tests equality of log fold increase in titer between groups.","statisticalMethod":"t-test, 2 sided"},{"groupIds":["OG000","OG001"],"groupDescription":"Day 183","nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","pValueComment":"GMFI estimates and 95% CIs are based on t-statistics assuming a normal distribution of the log fold increase in titer. p-value tests equality of log fold increase in titer between groups.","statisticalMethod":"t-test, 2 sided"}]},{"type":"SECONDARY","title":"Geometric Mean Fold Increase (GMFI) in Anti-CHIKV SNA Titers From Day 1 to Days 8, 15, 22, and 183 (Data Reported Per Arm)","description":"Geometric mean fold increase (GMFI) in anti-CHIKV SNA titers from Day 1 to Day 8, Day 15, Day 22, and Day 183 for the IEP for all age strata combined.\n\nFold rise in geometric mean titer is the ratio of the post-baseline value to the baseline value (e.g. number of 2 represents a post-baseline doubling of geometric mean titer).\n\nNumber analyzed is number of participants with a sample result available at both Day 1 and the indicated visit.","populationDescription":"Immunogenicity evaluable population (randomized and vaccinated participants who provided an evaluable Day 22 anti-CHIKV SNA sample within the analysis window, had no measurable anti-CHIKV SNA titer at Day 1, and had no reason to be excluded as defined prior to unblinding).","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Fold rise from baseline","timeFrame":"Day 8, 15, 22, and 183 (7,14, 21, and 182 days post-vaccination, respectively)","groups":[{"id":"OG000","title":"Group 1","description":"Group 1 - PXVX0317 lot 104\n\nCHIKV VLP/adjuvant: CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant 2%"},{"id":"OG001","title":"Group 2","description":"Group 2 - PXVX0317 lot 105\n\nCHIKV VLP/adjuvant: CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant 2%"},{"id":"OG002","title":"Group 3","description":"Group 3 - PXVX0317 lot 106\n\nCHIKV VLP/adjuvant: CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant 2%"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"841"},{"groupId":"OG001","value":"860"},{"groupId":"OG002","value":"858"}]}],"classes":[{"title":"Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"827"},{"groupId":"OG001","value":"848"},{"groupId":"OG002","value":"835"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12.0","lowerLimit":"10.9","upperLimit":"13.3"},{"groupId":"OG001","value":"12.9","lowerLimit":"11.7","upperLimit":"14.2"},{"groupId":"OG002","value":"12.5","lowerLimit":"11.3","upperLimit":"13.8"}]}]},{"title":"Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"800"},{"groupId":"OG001","value":"828"},{"groupId":"OG002","value":"806"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"143.1","lowerLimit":"130.8","upperLimit":"156.5"},{"groupId":"OG001","value":"148.3","lowerLimit":"135.7","upperLimit":"162.0"},{"groupId":"OG002","value":"147.0","lowerLimit":"134.3","upperLimit":"160.8"}]}]},{"title":"Day 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"841"},{"groupId":"OG001","value":"860"},{"groupId":"OG002","value":"858"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"212.3","lowerLimit":"194.4","upperLimit":"231.8"},{"groupId":"OG001","value":"218.6","lowerLimit":"200.4","upperLimit":"238.6"},{"groupId":"OG002","value":"216.3","lowerLimit":"198.1","upperLimit":"236.2"}]}]},{"title":"Day 183","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"752"},{"groupId":"OG001","value":"772"},{"groupId":"OG002","value":"777"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"44.1","lowerLimit":"40.5","upperLimit":"48.0"},{"groupId":"OG001","value":"45.6","lowerLimit":"41.9","upperLimit":"49.6"},{"groupId":"OG002","value":"45.4","lowerLimit":"41.7","upperLimit":"49.4"}]}]}]},{"type":"SECONDARY","title":"Number and Percentage of Participants With Anti-CHIKV SNA Titer ≥15 and 4-fold Rise Over Baseline at Days 8, 15, 22, and 183","description":"Number and percentage of participants with anti-CHIKV SNA titers ≥15 and 4-fold rise over baseline at Day 8, Day 15, Day 22, and Day 183 for the IEP for all age strata combined.\n\nNumber analyzed is number of participants with a sample result available at the indicated visit.","populationDescription":"Immunogenicity evaluable population (randomized and vaccinated participants who provided an evaluable Day 22 anti-CHIKV SNA sample within the analysis window, had no measurable anti-CHIKV SNA titer at Day 1, and had no reason to be excluded as defined prior to unblinding). Groups 1, 2, and 3 are combined, as participants received same treatment of PXVX0317 (dose, adjuvant, schedule), with only difference being the lot of manufactured vaccine. Data is reported for PXVX0317 vaccinated vs. placebo.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Day 8, 15, 22, and 183 (7,14, 21, and 182 days post-vaccination, respectively)","groups":[{"id":"OG000","title":"PXVX0317","description":"All participants that received active PXVX0317 vaccine, regardless of the manufactured vaccine lot. This includes all participants contained in Group 1, Group 2, and Group 3.\n\nCHIKV VLP/adjuvant: CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant 2%"},{"id":"OG001","title":"Placebo","description":"Group 4 - Placebo\n\nPlacebo: Placebo is comprised of formulation buffer"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2559"},{"groupId":"OG001","value":"424"}]}],"classes":[{"title":"SNA titers ≥15 at Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2510"},{"groupId":"OG001","value":"419"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"91.9","lowerLimit":"90.7","upperLimit":"92.9"},{"groupId":"OG001","value":"1.2","lowerLimit":"0.5","upperLimit":"2.8"}]}]},{"title":"SNA titers ≥15 at Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2434"},{"groupId":"OG001","value":"395"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"99.5","lowerLimit":"99.1","upperLimit":"99.7"},{"groupId":"OG001","value":"0.8","lowerLimit":"0.3","upperLimit":"2.2"}]}]},{"title":"SNA titers ≥15 at Day 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2559"},{"groupId":"OG001","value":"424"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"99.2","lowerLimit":"98.8","upperLimit":"99.5"},{"groupId":"OG001","value":"1.7","lowerLimit":"0.8","upperLimit":"3.4"}]}]},{"title":"SNA titers ≥15 at Day 183","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2301"},{"groupId":"OG001","value":"401"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"99.0","lowerLimit":"98.6","upperLimit":"99.4"},{"groupId":"OG001","value":"2.2","lowerLimit":"1.2","upperLimit":"4.2"}]}]},{"title":"≥4-fold rise over baseline at Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2510"},{"groupId":"OG001","value":"419"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"65.5","lowerLimit":"63.6","upperLimit":"67.3"},{"groupId":"OG001","value":"0.7","lowerLimit":"0.2","upperLimit":"2.1"}]}]},{"title":"≥4-fold rise over baseline at Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2434"},{"groupId":"OG001","value":"395"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"98.6","lowerLimit":"98.0","upperLimit":"99.0"},{"groupId":"OG001","value":"0.8","lowerLimit":"0.3","upperLimit":"2.2"}]}]},{"title":"≥4-fold rise over baseline at Day 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2559"},{"groupId":"OG001","value":"424"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"98.6","lowerLimit":"98.1","upperLimit":"99.0"},{"groupId":"OG001","value":"1.4","lowerLimit":"0.7","upperLimit":"3.1"}]}]},{"title":"≥4-fold rise over baseline at Day 183","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2301"},{"groupId":"OG001","value":"401"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"92.9","lowerLimit":"91.8","upperLimit":"93.9"},{"groupId":"OG001","value":"1.5","lowerLimit":"0.7","upperLimit":"3.2"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"SNA titers ≥15 at Day 8","nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","statisticalMethod":"Chi-squared","statisticalComment":"p-value is from a two-sided chi-square test of equality of seroresponse percentages between groups.","paramType":"Mean Difference (Final Values)","paramValue":"90.7","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"88.7","ciUpperLimit":"91.9","estimateComment":"Seroresponse rate difference is (PXVX0317 minus placebo)."},{"groupIds":["OG000","OG001"],"groupDescription":"SNA titers ≥15 at Day 15","nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","pValueComment":"p-value is from a two-sided chi-square test of equality of seroresponse percentages between groups.","statisticalMethod":"Chi-squared","paramType":"Mean Difference (Final Values)","paramValue":"98.7","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"97.2","ciUpperLimit":"99.3","estimateComment":"Seroresponse rate difference is (PXVX0317 minus placebo)."},{"groupIds":["OG000","OG001"],"groupDescription":"SNA titers ≥15 at Day 22","nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","statisticalMethod":"Chi-squared","statisticalComment":"p-value is from a two-sided chi-square test of equality of seroresponse percentages between groups.","paramType":"Mean Difference (Final Values)","paramValue":"97.6","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"95.8","ciUpperLimit":"98.5","estimateComment":"Seroresponse rate difference is (PXVX0317 minus placebo)."},{"groupIds":["OG000","OG001"],"groupDescription":"SNA titers ≥15 at Day 183","nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","statisticalMethod":"Chi-squared","statisticalComment":"p-value is from a two-sided chi-square test of equality of seroresponse percentages between groups.","paramType":"Mean Difference (Final Values)","paramValue":"96.8","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"94.8","ciUpperLimit":"97.9","estimateComment":"Seroresponse rate difference is (PXVX0317 minus placebo)."},{"groupIds":["OG000","OG001"],"groupDescription":"≥4-fold rise over baseline at Day 8","nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","statisticalMethod":"Chi-squared","statisticalComment":"p-value is from a two-sided chi-square test of equality of seroresponse percentages between groups.","paramType":"Mean Difference (Final Values)","paramValue":"64.8","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"62.5","ciUpperLimit":"66.7","estimateComment":"Seroresponse rate difference is (PXVX0317 minus placebo)."},{"groupIds":["OG000","OG001"],"groupDescription":"≥4-fold rise over baseline at Day 15","nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","statisticalMethod":"Chi-squared","statisticalComment":"p-value is from a two-sided chi-square test of equality of seroresponse percentages between groups.","paramType":"Mean Difference (Final Values)","paramValue":"97.8","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"96.3","ciUpperLimit":"98.4","estimateComment":"Seroresponse rate difference is (PXVX0317 minus placebo)."},{"groupIds":["OG000","OG001"],"groupDescription":"≥4-fold rise over baseline at Day 22","nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","statisticalMethod":"Chi-squared","statisticalComment":"p-value is from a two-sided chi-square test of equality of seroresponse percentages between groups.","paramType":"Mean Difference (Final Values)","paramValue":"97.2","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"95.5","ciUpperLimit":"98.1","estimateComment":"Seroresponse rate difference is (PXVX0317 minus placebo)."},{"groupIds":["OG000","OG001"],"groupDescription":"≥4-fold rise over baseline at Day 183","nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","statisticalMethod":"Chi-squared","statisticalComment":"p-value is from a two-sided chi-square test of equality of seroresponse percentages between groups.","paramType":"Mean Difference (Final Values)","paramValue":"91.4","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"89.4","ciUpperLimit":"92.7","estimateComment":"Seroresponse rate difference is (PXVX0317 minus placebo)."}]},{"type":"SECONDARY","title":"Number and Percentage of Participants With Anti-CHIKV SNA Titer ≥15 and 4-fold Rise Over Baseline at Days 8, 15, 22, and 183 (Data Reported Per Arm)","description":"Number and percentage of participants with anti-CHIKV SNA titers ≥15 and 4-fold rise over baseline at Day 8, Day 15, Day 22, and Day 183 for the IEP for all age strata combined.\n\nNumber analyzed is number of participants with a sample result available at the indicated visit.","populationDescription":"Immunogenicity evaluable population (randomized and vaccinated participants who provided an evaluable Day 22 anti-CHIKV SNA sample within the analysis window, had no measurable anti-CHIKV SNA titer at Day 1, and had no reason to be excluded as defined prior to unblinding).","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Day 8, 15, 22, and 183 (7,14, 21, and 182 days post-vaccination, respectively)","groups":[{"id":"OG000","title":"Group 1","description":"Group 1 - PXVX0317 lot 104\n\nCHIKV VLP/adjuvant: CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant 2%"},{"id":"OG001","title":"Group 2","description":"Group 2 - PXVX0317 lot 105\n\nCHIKV VLP/adjuvant: CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant 2%"},{"id":"OG002","title":"Group 3","description":"Group 3 - PXVX0317 lot 106\n\nCHIKV VLP/adjuvant: CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant 2%"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"841"},{"groupId":"OG001","value":"860"},{"groupId":"OG002","value":"858"}]}],"classes":[{"title":"SNA titers ≥15 at Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"827"},{"groupId":"OG001","value":"848"},{"groupId":"OG002","value":"835"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"90.9","lowerLimit":"88.8","upperLimit":"92.7"},{"groupId":"OG001","value":"93.6","lowerLimit":"91.8","upperLimit":"95.1"},{"groupId":"OG002","value":"91.0","lowerLimit":"88.9","upperLimit":"92.8"}]}]},{"title":"SNA titers ≥15 at Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"800"},{"groupId":"OG001","value":"828"},{"groupId":"OG002","value":"806"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"99.4","lowerLimit":"98.5","upperLimit":"99.7"},{"groupId":"OG001","value":"99.5","lowerLimit":"98.8","upperLimit":"99.8"},{"groupId":"OG002","value":"99.5","lowerLimit":"98.7","upperLimit":"99.8"}]}]},{"title":"SNA titers ≥15 at Day 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"841"},{"groupId":"OG001","value":"860"},{"groupId":"OG002","value":"858"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"99.3","lowerLimit":"98.5","upperLimit":"99.7"},{"groupId":"OG001","value":"99.2","lowerLimit":"98.3","upperLimit":"99.6"},{"groupId":"OG002","value":"99.2","lowerLimit":"98.3","upperLimit":"99.6"}]}]},{"title":"SNA titers ≥15 at Day 183","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"752"},{"groupId":"OG001","value":"772"},{"groupId":"OG002","value":"777"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"98.9","lowerLimit":"97.9","upperLimit":"99.5"},{"groupId":"OG001","value":"99.0","lowerLimit":"98.0","upperLimit":"99.5"},{"groupId":"OG002","value":"99.2","lowerLimit":"98.3","upperLimit":"99.6"}]}]},{"title":"≥4-fold rise over baseline at Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"827"},{"groupId":"OG001","value":"848"},{"groupId":"OG002","value":"835"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"66.7","lowerLimit":"63.5","upperLimit":"69.9"},{"groupId":"OG001","value":"66.0","lowerLimit":"62.8","upperLimit":"69.1"},{"groupId":"OG002","value":"63.7","lowerLimit":"60.4","upperLimit":"66.9"}]}]},{"title":"≥4-fold rise over baseline at Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"800"},{"groupId":"OG001","value":"828"},{"groupId":"OG002","value":"806"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"98.1","lowerLimit":"96.9","upperLimit":"98.9"},{"groupId":"OG001","value":"98.8","lowerLimit":"97.8","upperLimit":"99.3"},{"groupId":"OG002","value":"98.8","lowerLimit":"97.7","upperLimit":"99.3"}]}]},{"title":"≥4-fold rise over baseline at Day 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"841"},{"groupId":"OG001","value":"860"},{"groupId":"OG002","value":"858"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"98.7","lowerLimit":"97.7","upperLimit":"99.3"},{"groupId":"OG001","value":"98.7","lowerLimit":"97.7","upperLimit":"99.3"},{"groupId":"OG002","value":"98.5","lowerLimit":"97.4","upperLimit":"99.1"}]}]},{"title":"≥4-fold rise over baseline at Day 183","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"752"},{"groupId":"OG001","value":"772"},{"groupId":"OG002","value":"777"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"92.0","lowerLimit":"89.9","upperLimit":"93.8"},{"groupId":"OG001","value":"93.5","lowerLimit":"91.6","upperLimit":"95.1"},{"groupId":"OG002","value":"93.2","lowerLimit":"91.2","upperLimit":"94.7"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Adverse events were collected from Day 1 through to the Day 183 end of study visit.","description":"Solicited AE is a protocol-specified AE which is proactively asked of the participant during a protocol-specified time period (Systematic assessment).\n\nUnsolicited AE is spontaneously reported by participant or discovered by investigator (Non-systematic assessment).","eventGroups":[{"id":"EG000","title":"Group 1 - PXVX0317 Lot 104","description":"CHIKV VLP/adjuvant: CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant 2%","deathsNumAffected":0,"deathsNumAtRisk":918,"seriousNumAffected":10,"seriousNumAtRisk":918,"otherNumAffected":323,"otherNumAtRisk":918},{"id":"EG001","title":"Group 2 - PXVX0317 Lot 105","description":"CHIKV VLP/adjuvant: CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant 2%","deathsNumAffected":0,"deathsNumAtRisk":945,"seriousNumAffected":7,"seriousNumAtRisk":945,"otherNumAffected":375,"otherNumAtRisk":945},{"id":"EG002","title":"Group 3 - PXVX0317 Lot 106","description":"CHIKV VLP/adjuvant: CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant 2%","deathsNumAffected":1,"deathsNumAtRisk":927,"seriousNumAffected":6,"seriousNumAtRisk":927,"otherNumAffected":367,"otherNumAtRisk":927},{"id":"EG003","title":"Group 4 - Placebo","description":"Placebo: Placebo is comprised of formulation buffer","deathsNumAffected":0,"deathsNumAtRisk":464,"seriousNumAffected":1,"seriousNumAtRisk":464,"otherNumAffected":127,"otherNumAtRisk":464}],"seriousEvents":[{"term":"Arnold-Chiari malformation","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA (24.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"single reported event was a pre-existing condition diagnosed during the study","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":918},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":945},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":927},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":464}]},{"term":"Encephalocele","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA (24.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":918},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":945},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":927},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":464}]},{"term":"Retinal detachment","organSystem":"Eye disorders","sourceVocabulary":"MedDRA (24.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":918},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":945},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":927},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":464}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (24.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":918},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":945},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":927},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":464}]},{"term":"Cholecystitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA (24.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":918},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":945},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":927},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":464}]},{"term":"Anaphylactic reaction","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA (24.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":918},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":945},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":927},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":464}]},{"term":"Appendicitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (24.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":918},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":945},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":927},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":464}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (24.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":918},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":945},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":927},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":464}]},{"term":"Pyelonephritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (24.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":918},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":945},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":927},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":464}]},{"term":"Tubo-ovarian abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (24.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":918},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":945},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":927},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":464}]},{"term":"Craniocerebral injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (24.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":918},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":945},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":927},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":464}]},{"term":"Femoral neck fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (24.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":918},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":945},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":927},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":464}]},{"term":"Gun shot wound","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (24.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":918},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":945},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":927},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":464}]},{"term":"Road traffic accident","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (24.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":918},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":945},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":927},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":464}]},{"term":"Skin laceration","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (24.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":918},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":945},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":927},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":464}]},{"term":"Diabetic ketoacidosis","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (24.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":918},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":945},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":927},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":464}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (24.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":918},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":945},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":927},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":464}]},{"term":"Malignant melanoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA (24.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":918},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":945},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":927},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":464}]},{"term":"Basal ganglia infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (24.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":918},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":945},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":927},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":464}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (24.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":918},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":945},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":927},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":464}]},{"term":"Neuropathy peripheral","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (24.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":918},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":945},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":927},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":464}]},{"term":"Transient ischaemic attack","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (24.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":918},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":945},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":927},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":464}]},{"term":"Bipolar disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (24.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":918},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":945},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":927},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":464}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (24.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":918},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":945},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":927},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":464}]},{"term":"Nephrolithiasis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA (24.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":918},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":945},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":927},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":464}]},{"term":"Urinary retention","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA (24.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":918},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":945},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":927},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":464}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (24.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":918},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":945},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":927},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":464}]}],"otherEvents":[{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (24.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":64,"numAffected":64,"numAtRisk":918},{"groupId":"EG001","numEvents":79,"numAffected":75,"numAtRisk":945},{"groupId":"EG002","numEvents":78,"numAffected":73,"numAtRisk":927},{"groupId":"EG003","numEvents":31,"numAffected":31,"numAtRisk":464}]},{"term":"Injection site pain","organSystem":"General disorders","sourceVocabulary":"MedDRA (24.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":200,"numAffected":200,"numAtRisk":918},{"groupId":"EG001","numEvents":235,"numAffected":234,"numAtRisk":945},{"groupId":"EG002","numEvents":226,"numAffected":223,"numAtRisk":927},{"groupId":"EG003","numEvents":49,"numAffected":49,"numAtRisk":464}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA (24.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":171,"numAffected":169,"numAtRisk":918},{"groupId":"EG001","numEvents":201,"numAffected":198,"numAtRisk":945},{"groupId":"EG002","numEvents":192,"numAffected":190,"numAtRisk":927},{"groupId":"EG003","numEvents":79,"numAffected":79,"numAtRisk":464}]},{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"MedDRA (24.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":69,"numAffected":69,"numAtRisk":918},{"groupId":"EG001","numEvents":79,"numAffected":79,"numAtRisk":945},{"groupId":"EG002","numEvents":92,"numAffected":91,"numAtRisk":927},{"groupId":"EG003","numEvents":15,"numAffected":15,"numAtRisk":464}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (24.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":152,"numAffected":151,"numAtRisk":918},{"groupId":"EG001","numEvents":167,"numAffected":166,"numAtRisk":945},{"groupId":"EG002","numEvents":173,"numAffected":171,"numAtRisk":927},{"groupId":"EG003","numEvents":46,"numAffected":45,"numAtRisk":464}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (24.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":66,"numAffected":63,"numAtRisk":918},{"groupId":"EG001","numEvents":88,"numAffected":87,"numAtRisk":945},{"groupId":"EG002","numEvents":76,"numAffected":75,"numAtRisk":927},{"groupId":"EG003","numEvents":36,"numAffected":34,"numAtRisk":464}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (24.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":150,"numAffected":146,"numAtRisk":918},{"groupId":"EG001","numEvents":180,"numAffected":176,"numAtRisk":945},{"groupId":"EG002","numEvents":193,"numAffected":186,"numAtRisk":927},{"groupId":"EG003","numEvents":78,"numAffected":78,"numAtRisk":464}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"This is a multi-center study and agreements with investigators depends on the individual site contract."},"pointOfContact":{"title":"Medical Information","organization":"Bavarian Nordic","email":"medical.information_na@bavarian-nordic.com","phone":"1-844-422-8274"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2023-03-20","uploadDate":"2024-04-02T09:52","filename":"Prot_000.pdf","size":979157},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2023-03-20","uploadDate":"2024-04-02T09:53","filename":"SAP_001.pdf","size":759273}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09","submissionTracking":{"firstMcpInfo":{"postDateStruct":{"date":"2024-04-30","type":"ACTUAL"}}}},"conditionBrowseModule":{"meshes":[{"id":"D065632","term":"Chikungunya Fever"}],"ancestors":[{"id":"D018354","term":"Alphavirus Infections"},{"id":"D001102","term":"Arbovirus Infections"},{"id":"D000079426","term":"Vector Borne Diseases"},{"id":"D007239","term":"Infections"},{"id":"D000096724","term":"Mosquito-Borne Diseases"},{"id":"D014777","term":"Virus Diseases"},{"id":"D014036","term":"Togaviridae Infections"},{"id":"D012327","term":"RNA Virus Infections"}]}},"hasResults":true}